Loading stock data…
$2.21-0.10 (-4.13%)
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Rocket Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.21 with a market capitalization of $398M. Wall Street consensus targets $8.58 (12 analysts), implying a +289.1% move over the next 12 months. The stock is currently near its 52-week low of $2.18, remaining 37.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$46.92M↑ | -$48.51M↓ | -$44.03M↑ | -$52.42M↑ | -$67.68M |
| Net Income | $123.21M↑ | -$47.59M↓ | -$42.54M↑ | -$50.33M↑ | -$68.92M |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develo...